Building durable value across rare metabolic care.
A UK-based specialist healthcare company focused on practical innovation, disciplined execution and underserved metabolic patient populations.
Exploring partnerships, licensing or our development pipeline? Start here.
Specialised products for underserved metabolic patient populations.
Meta Healthcare develops and commercialises medicines, medical nutrition and medical foods for patients living with rare and inherited metabolic disorders.
Our mission is to improve outcomes for underserved metabolic patient populations through practical innovation and disciplined execution — building durable commercial value while remaining anchored to clinical need.
Why rare metabolic disorders.
- 01
Rare and inherited metabolic disorders affect small patient populations, but the unmet need within each indication is significant.
- 02
Specialised products — medicines, medical nutrition and medical foods — sit at the intersection of clinical, dietary and commercial considerations.
- 03
Differentiated formulations and disciplined orphan-pathway development create durable, defensible value across territories.
How we create value across the portfolio.
- 01
In-house R&D
A focused development capability spanning medicines, medical nutrition and medical foods — geared to underserved metabolic indications.
- 02
Orphan-pathway expertise
Experience navigating FDA, EMA and MHRA orphan-designation routes to support development of rare disease programmes.
- 03
Regional licensing
A network of regional partners supporting commercialisation in territories where local expertise is decisive.
- 04
Commercial discipline
Funded development programmes and retained long-term value in key territories.
United Kingdom.
Meta Healthcare is headquartered in the United Kingdom, with regional partners supporting commercialisation across Europe, the Middle East and North Africa, and selected international markets.
For corporate, partnership or licensing enquiries, contact contact@metahealthcare.example.
Regional licensing and co-development opportunities across our pipeline.
Funded development programmes, orphan-designated assets and differentiated medical nutrition formulations — open to structured partner collaborations.
Explore the pipeline or jump straight to partnership routes.
